02.09.2022
Prevention
$2,019,891.00
36 months
Very Early Onset Inflammatory Bowel Disease (VEOIBD): Precision Molecular Diagnoses to Targeted Therapies: Munich Studies
The lack of standard of care in the evaluation and treatment of VEOIBD has hindered the accelerated development of personalized therapeutics for these patients. If successful, this study will improve diagnostics and identify novel personalized therapies for children with VEOIBD and will develop a widely applicable genomic medicine pipeline for Crohn's disease.